Australian researchers have tested a miracle drug that they say “melts cancer cells away”, hailing it as a breakthrough for cancer patients worldwide.
The drug targets a specific protein that enables cancer to survive. During a Melbourne-based trial, researchers tested 116 patients over four years and discovered that the drug Venetoclax significantly reduces cancer blood cells.
Positive results were seen in 79 percent of cases involving patients suffering from chronic lymphocytic leukemia. Some patients who had previously undergone treatment were left as good as new after agreeing to the new pill trials.
This is indeed historic news, as it marks the first trial of a medicine that is the result of three decades of research. “Here we are a bit under 30 years later in collaboration with WEHI and pharmaceutical companies here and in the US having proved that’s achievable,” head of haemotology, Professor John Seymour, told the Sydney Morning Herald.
“This is a completely new class of drugs and there is no other drug or medicine previously available that has had the ability to inhibit this BCL-2 protein,” he said, adding that the drug’s benefits also spread to other forms of cancer and leukemia than those tested.
Their results are published Thursday in the journal New England Journal of Medicine.
Success stories were heard from many chronically sick patients. One, Rodney Jacobs, 63, who owns a record shop in Melbourne, told the newspaper he was referred to the trial in 2012 after other therapies, including chemotherapy. Jacobs could not get a break.
“It was looking pretty bleak at that stage,” he told the paper. “The results have been nothing short of stunning… I’ve had little or no side effects and I slowly got myself back to work with my business and slowly but surely I have a relatively normal life.”
Roberts explained how the drug works, and it has to do with a specific protein called BCL-2, which helps cancer cells survive, making them simply “melt away.” It was first discovered in the 1980s, but scientists couldn’t find an inhibitor for it.
“I think this drug is going to be very significant and I think these results are significant in themselves because they show in real people exactly what the potential of this can be,” Roberts says. “Many of the people who achieved a complete remission are still in a complete remission more than a year later.”
Latest posts by Sean Adl-Tabatabai (see all)
- FBI Reopen Hillary Clinton Email Investigation, New Emails Found - October 28, 2016
- Morrissey Declares Brexit “Magnificent” Win For British Democracy - October 27, 2016
- Scientists Told To ‘Remain Silent’ On Glyphosate Cancer Findings - October 27, 2016